Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861784 | 1.00 | POLA1 (0.42) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861827 | 0.93 | P2RY2 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861826 | 0.93 | P2RY2 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861904 | 0.91 | P2RY2 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861762 | 0.91 | P2RY2 (0.40) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861737 | 0.89 | P2RY2 (0.39) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL20227089 | 0.89 | P2RY2 (0.39) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861900 | 0.89 | POLA1 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861892 | 0.89 | POLA1 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 | |
| SCHEMBL19861905 | 0.88 | P2RY2 (0.41) | POLA1P2RY2P2RY4ENPP1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9890188-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | POLA1 562/4885P2RY2 160/4885P2RY4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.